First-line icotinib versus cisplatine/pemetrexed plus pemetrexed maintenance therapy in lung adenocarcinoma patients with sensitizing EGFR mutation (CONVINCE).
Year: 2016
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: Chinese Academy of Medical Sciences & Peking Union Medical College, Cancer Hospital of Chinese Academy of Medical Sciences, Shanghai Chest Hospital, Jilin University, First Hospital of Jilin University, Sichuan Cancer Hospital, First Hospital of China Medical University, Fourth Hospital of Hebei Medical University, Shanxi Provincial Cancer Hospital, Henan Cancer Hospital, Xijing Hospital, Jiangsu Cancer Hospital, Tang Du Hospital, Air Force Medical University, Harbin Medical University, Peking University, Nanjing General Hospital of Nanjing Military Command, Capital Medical University, Beijing Chest Hospital, Betta Pharmaceuticals (China), First Affiliated Hospital Zhejiang University
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2723308302